 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
33 News |  |
- || Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Pharma
Clinical, Retrospective data, Journal: Comparison of Efficacies of a Blonanserin Transdermal Patch and Blonanserin Oral Formulation for Psychiatric Symptoms in Patients With Schizophrenia Treated With Laxatives Using a Japanese Claims Database. (Pubmed Central) - Feb 21, 2025
No significant difference was observed in the risk of hospitalization for patients with schizophrenia treated with laxatives between the BNS patch and BNS oral groups. The effectiveness of antipsychotic patches in these patients warrants further research that considers factors such as patch preference in the elderly.
- || Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Pharma
Clinical, Retrospective data, Journal: Association between treatment response and dose of blonanserin transdermal patch in patients with acute schizophrenia: A post hoc cluster analysis based on baseline psychiatric symptoms. (Pubmed Central) - Dec 2, 2024
BNS-P exhibited a dose-dependent antipsychotic effect in all clusters, particularly highlighting its efficacy in patients with predominant positive symptoms, even at lower doses. These findings provide novel and valuable insights for determining BNS-P dose tailoring to individual symptomatic characteristics in real-world practice.
- | Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Pharma
Journal: Successful Management of Terminal Delirium With Transdermal Blonanserin Patch in a Terminally Ill Cancer Patient. (Pubmed Central) - Aug 21, 2024
However, he deteriorated a week later with an estimated survival of days, ultimately requiring continuous midazolam for refractory agitation. This case underscores the potential of transdermal blonanserin patches for delirium in terminally ill cancer patients, emphasizing the need for future prospective studies.
- || Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Pharma
Review, Journal, Metastases: Novel therapies for nausea and vomiting in advanced illness and supportive cancer care. (Pubmed Central) - Jun 10, 2024
Isopropyl alcohol aromatherapy has been successfully used in the emergency department for nausea and vomiting with an onset to benefit more rapidly than standard antiemetics. Isopropyl alcohol prep pads can be used for home-going antiemetic therapy and as a bridge to treating acute nausea until standard antiemetics take effect.
- Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Pharma
Efficacy of Blonanserin Transdermal Patch on Terminal Delirium in Patients with Respiratory Diseases (PS-1 in poster area) - Jun 17, 2023 - Abstract #ERS2023ERS_4265;
Isopropyl alcohol prep pads can be used for home-going antiemetic therapy and as a bridge to treating acute nausea until standard antiemetics take effect. Palliative care; General respiratory patient care; Pulmonary function testing; Cell and molecular biology; Epidemiology; Public health; Imaging
- | Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Dainippon
Observational data, Retrospective data, Journal: Acceptability of transdermal antipsychotic patches by patients who refuse oral medication and their effectiveness in preventing recurrence of delirium: a retrospective observational study. (Pubmed Central) - Aug 22, 2022
Instead, a transdermal patch of blonanserin, a second-generation antipsychotic drug, was tried...The present findings suggest that transdermal antipsychotic patches are more likely to be accepted by patients who refuse oral medications. Prospective studies are needed.
- | Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Dainippon
Journal: Prediction of Corresponding Dose of Transdermal Blonanserin to Oral Dose Based on Dopamine D2 Receptor Occupancy: Unique Characteristics of Blonanserin Transdermal Patch. (Pubmed Central) - May 4, 2022
Prospective studies are needed. Predicted D2 occupancy suggested that a 40- to 80-mg/d blonanserin transdermal patch dose corresponds to an 8- to 24-mg/d oral dose for the treatment of schizophrenia.
- | Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Dainippon
Journal: Early improvement as a predictor of response to blonanserin transdermal patch in patients with schizophrenia. (Pubmed Central) - Mar 29, 2022
Predicted D2 occupancy suggested that a 40- to 80-mg/d blonanserin transdermal patch dose corresponds to an 8- to 24-mg/d oral dose for the treatment of schizophrenia. No abstract available
- || Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Dainippon
Clinical, Journal: Switching from blonanserin oral tablets/powders to transdermal patches alleviates extrapyramidal symptoms in patients with schizophrenia: A 52-week open-label study. (Pubmed Central) - Feb 25, 2022
In cohort 1 (n = 97), patients received 40-80 mg/day blonanserin transdermal patches for one year after taking 8-16 mg/day blonanserin tablets for 6 weeks, and the dose of patches was determined based on the dose of the tablets...Changes from the start of transdermal patch treatment in EPS and the dose of antiparkinsonian drugs at 3, 6, and 12 months were assessed using the Drug-Induced EPS Scale (DIEPSS) and biperiden equivalents of total antiparkinsonian drugs (BPD-eq), respectively...In contrast, there were no significant changes from the start of patch treatment in BPD-eq at any month (p > 0.05). Transdermal patches of blonanserin are a more effective route of administration to diminish EPS than oral tablets/powder.
- || Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Dainippon
Clinical, P2 data, Journal: Striatal dopamine D2 receptor occupancy induced by daily application of blonanserin transdermal patches: Phase 2 study in Japanese patients with schizophrenia. (Pubmed Central) - Jan 29, 2022
Blonanserin patches (40/80 mg/day) have lower diurnal variability in occupancy than blonanserin tablets (8/16 mg/day) and patches at doses of 40 mg/day and 80 mg/day appear to be suitable alternative for blonanserin tablets at doses of 8 mg and 16 mg/day, respectively. Blonanserin patches represent a potential new treatment option for patients with schizophrenia.
- || Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Dainippon
Clinical, Journal: Use of Blonanserin Transdermal Patch in Home Treatment of Schizophrenia: A Case Study. (Pubmed Central) - Jan 27, 2022
Blonanserin patches represent a potential new treatment option for patients with schizophrenia. No abstract available
- || Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Dainippon
Clinical, PK/PD data, Journal: Pharmacokinetic evaluation of blonanserin transdermal patch: Population analysis and simulation of plasma concentration and dopamine D receptor occupancy in clinical settings. (Pubmed Central) - Dec 23, 2021
In the case of failure to remove the previous patch or a missing application, the increase or decrease in plasma concentration and dopamine D receptor occupancy was less than 20%. These results indicated that the plasma blonanserin concentration and dopamine D receptor occupancy were stable after blonanserin transdermal patch application, which may lead to improved tolerability during the treatment of patients with schizophrenia.
- || Rexulti (brexpiprazole) / Lundbeck, Otsuka
Retrospective data, Review, Journal: Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan. (Pubmed Central) - Jul 7, 2021
These results indicated that the plasma blonanserin concentration and dopamine D receptor occupancy were stable after blonanserin transdermal patch application, which may lead to improved tolerability during the treatment of patients with schizophrenia. Our results are similar to those of previous network meta-analysis involving various races and ethnicities.
- || Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Dainippon
Clinical, Journal: Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study. (Pubmed Central) - Jun 10, 2021
P3
Blonanserin transdermal patches are safe and effective in the long-term treatment of schizophrenia. CLINICALTRIALS.
- Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Dainippon
[VIRTUAL] Efficacy and Safety of Blonanserin Transdermal Patch in Patients with Schizophrenia: A Multicenter Open-Label Extension Study () - Mar 7, 2021 - Abstract #CINP2021CINP_133;
CLINICALTRIALS. BNS transdermal patch improved the symptoms of acute schizophrenia with acceptable tolerability, and no negative findings were observed even with long-term use.
- Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Dainippon
[VIRTUAL] Efficacy and Safety of Blonanserin Transdermal Patch in Patients with Schizophrenia: A 6-Week Randomized, DoubleBlind, Placebo Controlled, Multicenter Study () - Mar 7, 2021 - Abstract #CINP2021CINP_132;
P3
BNS transdermal patch improved the symptoms of acute schizophrenia with acceptable tolerability, and no negative findings were observed even with long-term use. BNS transdermal patch improved the symptoms of acute schizophrenia with acceptable Tolerability.
- ||| Saphris (asenapine) / Lundbeck, Meiji Seika, AbbVie, Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Dainippon
Clinical, P3 data, Review, Journal: Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan. (Pubmed Central) - Feb 9, 2021
BNS transdermal patch improved the symptoms of acute schizophrenia with acceptable Tolerability. BLO-P40+80 may have a good efficacy/safety/tolerability profile for the treatment of patients with acute schizophrenia.
- || Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Dainippon
Clinical, Journal: Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study. (Pubmed Central) - Jan 21, 2021
BLO-P40+80 may have a good efficacy/safety/tolerability profile for the treatment of patients with acute schizophrenia. Blonanserin transdermal patch improved the symptoms of acute schizophrenia with acceptable tolerability.
- | Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Dainippon
Journal: Blonanserin patch for schizophrenia. (Pubmed Central) - Jan 21, 2021
Blonanserin transdermal patch improved the symptoms of acute schizophrenia with acceptable tolerability. No abstract available
- | Journal: Transdermal Delivery of Antipsychotics: Rationale and Current Status. (Pubmed Central) - Sep 23, 2020
Despite the current availability of a large number of antipsychotics, only a few of these drugs (e.g. aripiprazole, asenapine, blonanserin, chlorpromazine, haloperidol, olanzapine, prochlorperazine, quetiapine, and risperidone) have been developed as transdermal delivery systems...However, few clinical trials on transdermal delivery of antipsychotic drugs are available and only delivery systems containing asenapine and blonanserin have shown interesting clinical results in terms of pharmacokinetic data, efficacy, and tolerability. Recently, the transdermal patch formulation of blonanserin was approved in Japan for the treatment of schizophrenia.
- || Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Dainippon
Clinical, Journal: Prediction methods of drug-drug interactions of non-oral CYP3A4 substrates based on clinical interaction data after oral administrations - Validation with midazolam, alfentanil, and verapamil after intravenous administration and prediction for blonanserin transdermal patch. (Pubmed Central) - Jul 15, 2020
Predicted AUCRs of midazolam, alfentanil and R- and S-verapamil were less than, but not far from observed ratios, suggesting good conservative prediction. These methods were applied to blonanserin transdermal patch, suggesting much smaller interaction with CYP3A4 inhibitors/inducers compared to oral dosage of blonanserin.
- | Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Pharma
Trial completion: Confirmatory Study of DSP-5423P in Patients With Schizophrenia (clinicaltrials.gov) - Jul 24, 2019
P3, N=580, Completed, Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
These methods were applied to blonanserin transdermal patch, suggesting much smaller interaction with CYP3A4 inhibitors/inducers compared to oral dosage of blonanserin. Recruiting --> Completed
- ||||||| Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Pharma
Trial completion: Long-term Study of DSP-5423P in Patients With Schizophrenia (clinicaltrials.gov) - Jul 25, 2017
P3, N=203, Completed, Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Pharma
Enrollment change, Trial initiation date, Trial primary completion date: Confirmatory Study of DSP-5423P in Patients With Schizophrenia (clinicaltrials.gov) - Jul 23, 2016
P3, N=501, Recruiting, Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
Active, not recruiting --> Completed N=360 --> 501 | Initiation date: Nov 2014 --> Aug 2014 | Trial primary completion date: Apr 2018 --> Dec 2018
- ||||| Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Pharma
Enrollment closed, Trial primary completion date: Long-term Study of DSP-5423P in Patients With Schizophrenia (clinicaltrials.gov) - Jul 23, 2016
P3, N=200, Active, not recruiting, Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
N=360 --> 501 | Initiation date: Nov 2014 --> Aug 2014 | Trial primary completion date: Apr 2018 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Jul 2017
- | Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Pharma
Enrollment open: Long-term Study of DSP-5423P in Patients With Schizophrenia (clinicaltrials.gov) - Mar 24, 2015
P3, N=200, Recruiting, Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Jul 2017 Not yet recruiting --> Recruiting
- | Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Pharma
Enrollment open: Confirmatory Study of DSP-5423P in Patients With Schizophrenia (clinicaltrials.gov) - Feb 2, 2015
P3, N=360, Recruiting, Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Pharma
New P3 trial: Long-term Study of DSP-5423P in Patients With Schizophrenia (clinicaltrials.gov) - Jan 12, 2015
P3, N=200, Not yet recruiting, Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
- || Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Pharma
New P3 trial: Confirmatory Study of DSP-5423P in Patients With Schizophrenia (clinicaltrials.gov) - Nov 11, 2014
P3, N=360, Not yet recruiting, Sponsor: Sumitomo Dainippon Pharma Co., Ltd.